Drugs / Lopinavir/ritonavir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00866021 | Feb 2008 → Jun 2012 | HIV infectious disease, hepatitis C virus infection | Fundacion SEIMC-GESIDA | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lopinavir/ritonavir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00866021 ↗ |
| Known as | LPV/r | “Lopinavir/ritonavir (LPV/r) is a potent HIV protease inhibitor and is characterized by a very high pharmacological and genetic barrier.” NCT00866021 ↗ |
| Action | Inhibit | “Lopinavir/ritonavir (LPV/r) is a potent HIV protease inhibitor” NCT00866021 ↗ |